CEPHALOSPORIN DRUGS MARKET ANALYSIS

Name: Cephalosporin Drugs Market Size and Trends
Creator: Coherent Market Insights
License: https://www.coherentmarketinsights.com/privacy-policy
Keywords: Cephalosporin Drugs Market, Cephalosporin Drugs Market Report, Cephalosporin Drugs Industry Report, Cephalosporin Drugs Market Size, Cephalosporin Drugs Market Share, Cephalosporin Drugs Market Analysis, Cephalosporin Drugs Market Growth, Cephalosporin Drugs Market Trends, Cephalosporin Drugs Market Overview, Cephalosporin Drugs Market Forecast

Cephalosporin Drugs Market, By Generation (First-generation, Cephalosporin, Second-generation Cephalosporin, Third-generation Cephalosporin, Fourth-generation Cephalosporin, and Fifth-generation Cephalosporin), By Type (Branded Cephalosporin Drugs and Generic Cephalosporin Drugs), By Formulation (Oral (Tablets, Capsules, and Liquid) and Injection), By Indication (Respiratory Tract Infection, Skin Infection, Ear Infection, Bacterial Infection, Urinary Tract Infection, Sexually Transmitted Infection, Sinus Infection, Surgical Prophylaxis, and Others (Meningitis, Acute Abdomen Infection, and Pelvic infection)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Trends, and Forecast 2019 - 2026

Published In : Jul 2019
Code : CMI2893
Pages :236
Formats :
Excel and PDF
Industry : Pharmaceutical

Cephalosporin Drugs MarketSize and Trends

The global cephalosporin drugs market size was valued at US$ 14,240.0 million in 2018, and is expected to witness a CAGR of 3.8% over the forecast period (2019 – 2026).

Global Cephalosporin Drugs Market Share (%) Analysis, By Generation, 2018 & 2026

Source: Coherent Market Insights Analysis (2019)

Increasing Drug Approvals and R&D Activities is expected to Drive Growth of the Cephalosporin Drugs Market

Approvals and launch of novel products is expected to be a major factor driving the global cephalosporin drugs market growth over the forecast period. For instance, in June 2019, Merck & Co. announced that the U.S. Food and Drug Administration (FDA) approved its supplemental New Drug Application (sNDA) for the use of ZERBAXA (ceftolozane and tazobactam) for the treatment of patients 18 years and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Increasing research and development activities has spurred growth of the cephalosporin drugs market. For instance, in November 2017, B. Braun Medical Inc. initiated a clinical trial of Cefazolin infusion evaluating the safety of 1 g and 2 g of Cefazolin in pediatric subjects. The study is in phase 4 and is expected to be completed in July 2019. Therefore, increasing research on cephalosporin drugs is expected to create a favorable environment for the cephalosporin drugs market growth over the forecast period.